DAS181 treatment of severe lower respiratory tract parainfluenza virus infection in immunocompromised patients: A phase 2 randomized, placebo-controlled study
Clinical infectious diseases
Open Access Publication
Rights and Permissions
Roy F Chemaly, Francisco M Marty, Cameron R Wolfe, Steven J Lawrence, Sanjeet Dadwal, Rosemary Soave, Jason Farthing, Stephen Hawley, Paul Montanez, Jimmy Hwang, Jennifer Hui-Chun Ho, Stanley Lewis, George Wang, Michael Boeckh, DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study, Clinical Infectious Diseases, Volume 73, Issue 3, 1 August 2021, Pages e773–e781, https://doi.org/10.1093/cid/ciab113. © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact email@example.com.
Chemaly, Roy F; Marty, Francisco M; Wolfe, Cameron R; Lawrence, Steven J; Dadwal, Sanjeet; Soave, Rosemary; Farthing, Jason; Hawley, Stephen; Montanez, Paul; Hwang, Jimmy; Ho, Jennifer Hui-Chun; Lewis, Stanley; Wang, George; and Boeckh, Michael, "DAS181 treatment of severe lower respiratory tract parainfluenza virus infection in immunocompromised patients: A phase 2 randomized, placebo-controlled study." Clinical infectious diseases. 73, 3. e773 - e781. (2021).
Supplemental material is available for this article at publisher site.